Fig. 5

Silencing AC010883.5 inhibited tumor cell proliferation and progression by inactivating the MAPK signaling pathway. A. Tumor xenografts images on the day of sacrifice (day 33; N = 6). B. Dissected tumor tissue growth with AC010883.5 pLVX-shRNAs-puro SiHa cells. C. Dissected tumor tissue weight with AC010883.5 pLVX-shRNAs-puro SiHa cells. D. AC010883.5 expression in SiHa cells transfected with pLVX-shRNAs-puro in tumor tissue. E–G. PCNA and Ki67 expression in C-33A cells were detected by immunohistochemistry staining of the tumor tissue. H. ERK1/2, p-ERK, MEK1/2, and p-MEK protein levels with pLVX-shRNAs-puro SiHa cells by western blot; N = 6; *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations: MAPK, mitogen-activated protein kinase; PCNA, proliferating cell nuclear antigen; ERK1/2, extracellular signal-regulated kinase 1/2; p-ERK1/2, phosphorylated ERK1/2; MEK1/2, MAPK kinase 1/2; p-MEK1/2, phosphorylated MEK1/2